IRLAB gets back mesdopetam rights - ABG

IRLAB gets back mesdopetam rights from Ipsen
Plans to move mesdopetam into Ph 3 confirmed
Conf call tomorrow at 10:00 CET


IRLAB & Ipsen part ways: IRLAB regains mesdopetam rights

Today IRLAB released two press releases about mesdopetam, their drug candidate addressing Parkinson's disease levodopa-induced dyskinesia (PD-LIDs). In the first press release, IRLAB announced the reacquisition of mesdopetam's rights from Ipsen, regaining full control of the clinical development and eventual commercialisation of the drug candidate. As part of this rights transfer, IRLAB has agreed to pay Ipsen a low-single-digit royalty based on future product sales.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2023/8/irlab-therapeutics---irlab-gets-back-mesdopetam-rights/